India Pharma a Long-Term Buy Despite Premium Valuations, Expert Says

Sudip Bandyopadhyay backs domestic pharma, CDMOs and hospitals on rising demand and stronger fundamentals, but offers no stock picks or price targets.

bt-corporate · 6/30/2026, 10:02:40 AM · Ask about this →